Targeting S100A9-ALDH1A1-Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer.
Anup Kumar BiswasSeoyoung HanYifan TaiWanchao MaCourtney CokerS Aidan QuinnAhmad Rushdi ShakriTimothy James ZhongHanna ScholzeGalina G LagosAngeliki MelaKatia ManovaElisa de StanchinaAdolfo A FerrandoCathy Lee MendelsohnPeter CanollHelena A YuPaul K PaikAnjali SaqiCatherine A ShuMark G KrisJoan MassaguéSwarnali AcharyyaPublished in: Cancer discovery (2022)
Treatment with the EGFR TKI osimertinib prolongs the survival of patients with EGFR-mutant lung cancer; however, patients develop metastatic relapses, often to the brain. We identified a novel intracellular S100A9-ALDH1A1-RA signaling pathway that drives lethal brain relapse and can be targeted by pan-RAR antagonists to prevent cancer progression and prolong patient survival. This article is highlighted in the In This Issue feature, p. 873.
Keyphrases
- small cell lung cancer
- epidermal growth factor receptor
- tyrosine kinase
- resting state
- free survival
- white matter
- signaling pathway
- advanced non small cell lung cancer
- functional connectivity
- ejection fraction
- cancer therapy
- cerebral ischemia
- newly diagnosed
- machine learning
- squamous cell carcinoma
- rheumatoid arthritis
- papillary thyroid
- case report
- prognostic factors
- deep learning
- wild type
- pi k akt
- patient reported outcomes
- brain injury
- drug delivery
- squamous cell
- systemic lupus erythematosus
- subarachnoid hemorrhage
- lymph node metastasis